← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06520982

NCT06520982 Early Neurovascular Adaptations in Aging Women

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06520982
Status Recruiting
Phase EARLY_Phase 1
Sponsor University of Missouri-Columbia
Condition Women
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2024-09-20
Primary Completion 2027-06-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
NorepinephrineIsoproterenolAcetylcholine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 64 participants in total. It began in 2024-09-20 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Our goal is to enhance our understanding of early vascular adaptations in aging women with an emphasis on the sympathetic nervous system.

Eligibility Criteria

Inclusion Criteria: * Assigned female at birth (AFAB) * 18-70 years of age Exclusion Criteria: * Assigned male at birth (AMAB) * Pregnancy, breastfeeding * Body mass index ≥30 kg/m2 * Taking medications known to affect metabolic, autonomic, and/or respiratory function * Oral hormonal contraception in last 6 month * History of hormone replacement therapy * History of hyster- or oophor-ectomy * Current smoking/Nicotine use * Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy * Chronic disease * Blood pressure ≥140/90 mmHg * Communication barriers

Contact & Investigator

Central Contact

Jacqueline K Limberg

✉ limbergj@missouri.edu

📞 573-882-2420

Frequently Asked Questions

Who can join the NCT06520982 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Women. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06520982 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT06520982 currently recruiting?

Yes, NCT06520982 is actively recruiting participants. Contact the research team at limbergj@missouri.edu for enrollment information.

Where is the NCT06520982 trial being conducted?

This trial is being conducted at Columbia, United States.

Who is sponsoring the NCT06520982 clinical trial?

NCT06520982 is sponsored by University of Missouri-Columbia. The trial plans to enroll 64 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology